DRAK2 Antikörper (Internal Region)

Produktnummer ABIN499168

Produktdetails anti-DRAK2 Antikörper

Target: DRAK2 (STK17B) (serine/threonine Kinase 17b (STK17B))

Bindungsspezifität: Internal Region

Reaktivität: Human, Hund

Wirt: Ziege

Klonalität: Polyklonal

Konjugat: Dieser DRAK2 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB)

Sequenz: C-HSVRSSEDKT SK

Spezifität: This antibody detects STK17B / DRAK2 (Internal).

Kreuzreaktivität (Details): Species reactivity (expected):DogSpecies reactivity (tested):Human

Aufreinigung: Ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide

Immunogen: Peptide from the internal region of the protein sequence according to NP_004217.1

Anwendungsinformationen

Applikationshinweise: Peptide ELISA: antibody detection limit dilution 1: 32000. Western blot: 1-3 μg/mL. Approx 45 kDa band observed in lysates of cell line MOLT4(calculated MW of 42.5 kDa according to NP_004217.1).
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 0.5 mg/mL

Buffer: Tris saline, 0.02 % sodium azide, pH 7.3 with 0.5 % bovine serum albumin

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handhabung: Avoid repeated freezing and thawing.

Lagerung: 4 °C/-20 °C

Informationen zur Lagerung: Store at 2 - 8 °C up to one week or (in aliquots) at -20 °C for longer.

Details zu DRAK2

Target: DRAK2 (STK17B) (serine/threonine Kinase 17b (STK17B))

Andere Bezeichnung: STK17B / DRAK2 (STK17B Produkte)

Synonyme: zgc:65989 antikoerper, STK17B antikoerper, DRAK2 antikoerper, Drak2 antikoerper, 3110009A03Rik antikoerper, AI120141 antikoerper, serine/threonine kinase 17b (apoptosis-inducing) antikoerper, serine/threonine kinase 17b antikoerper, stk17b antikoerper, STK17B antikoerper, Stk17b antikoerper

Hintergrund: Apoptosis is mediated by death domain containing adapter molecules and a caspase family of proteases. Certain serine/threonine protein kinases, such as ASK1 and RIP, are mediators of apoptosis. Two novel serine/threonine kinases that induce apoptosis were recently identified and designated DRAK1 and DRAK2 (for DAP kinase related apoptosis inducing protein kinases). DRAKs contain an N terminal kinase domain and a C terminal regulation domain. Overexpression of DRAK2 induces apoptosis. DRAKs have high sequence homology to DAP and ZIP kinases, and they represent a novel family of serine/threonine kinases, which mediates apoptosis through their catalytic activities. DRAK2 is located in nucleus and the messenger RNA was ubiquitously expressed in human tissues. Apoptosis is mediated by death domain containing adapter molecules and a caspase family of proteases. Certain serine/threonine protein kinases, such as ASK-1 and RIP,are mediators of apoptosis. Two novel serine/threonine kinases that induce apoptosis were recently identified and designated DRAK1 and DRAK2 (for DAP kinase-related apoptosis-inducing protein kinases) (1). DRAKs contain anN-terminal kinase domain and a C-terminal regulation domain. Overexpression of DRAK2 induces apoptosis. DRAKs have high sequence homology to DAP and ZIP kinases, and they represent a novel family of serine/threonine kinases, which mediates apoptosis through their catalytic activities. DRAK2 is located in nucleus and the messenger RNA was ubiquitously expressed in human tissues.Synonyms: DAP kinase-related apoptosis-inducing protein kinase 2, Serine/threonine-protein kinase 17B

Gen-ID: 9262

NCBI Accession: NP_004217

UniProt: O94768